ScripExelixis may have a steady source of revenue after cabozantinib – approved as Cabometyx and Cometriq – loses market exclusivity, after zanzalintinib delivered positive pivotal Phase III results in col
ScripMerck & Co’s PD-1 inhibitor for multiple cancer indications Keytruda (pembrolizumab) comfortably retained its number one spot as the drug generating the highest global revenues in the first quarte
ScripHuntington’s disease (HD) has been a notoriously difficult field for drug development but enthusiasm is growing, not least at Skyhawk Therapeutics which has initiated a Phase II/III trial on a potenti
Pink SheetTop cell and gene therapy regulators Nicole Verdun and her deputy Rachael Anatol were forced out of the US Food and Drug Administration June 18, per multiple sources familiar with the matter. A commen